MOSCOW (Sputnik) – Russia is predicted to ramp up the manufacturing of the Sputnik V vaccine towards the coronavirus by 30 million doses by June, Russian Minister of Trade and Industry Denis Manturov stated Thursday.
“Speaking of production, more than 2.5 million doses will have been produced in December, slightly less for the civilian use. But in January, according to the plans that have already been prepared and approved by the manufacturers, the number will be 3.5 [million], then it will grow to 18 by April, and 30 by June. But I am somewhat optimistic that it may happen even earlier than that,” Manturov stated in an interview with the RBC broadcaster.
During the COVID-19 pandemic, Russia emerged as a frontrunner in vaccine growth, as two of its merchandise, Sputnik V, developed by Moscow’s Gamaleya Institute, and EpiVacCorona, developed by Siberia’s analysis heart Vector, are already within the Phase 3 trials. Another vaccine, by the Chumakov analysis heart of the Russian Academy of Sciences, will start Phase 3 trials early in 2021. The scientific trials of the trailblazer Sputnik V vaccine have demonstrated that its efficacy fee is over 90 %.